Evaluation of toxicity of topiramate exposures reported to poison centers.
Published literature on the toxicity of a topiramate overdose is limited to case reports. This retrospective study of poison center data was performed to examine the severity of topiramate overdoses. Data on single substance exposures to topiramate reported to the American Association of Poison Control Centers (AAPCC) Toxic Exposure Surveillance System (TESS) in 2000 and 2001 were retrospectively analysed. A total of 567 cases met the inclusion criteria, of which 39% occurred in adults over 19 years of age and 30.2% in children < or = 4 years old. The majority of patients (62.1%) experienced no toxicity. The most common clinical effects reported were drowsiness/lethargy (15.5%), dizziness/vertigo (4.9%), agitation (4.9%), confusion (3.9%), nausea (2.6%) and vomiting (2.5%). Symptomatic patients were older than asymptomatic patients and adults were more likely to be managed in a healthcare facility (P <0.0001). Patients who received gastrointestinal decontamination experienced less serious outcomes than those without decontamination (P <0.02). It is concluded that clinicians should expect relatively mild mental status changes in adults or children with toxicity from topiramate overdose. Serious toxic effects, such as CNS depression with respiratory depression or persistent non-anion gap metabolic acidosis, are infrequent.
Lofton
A L
AL
Beverly Hospital, Northeast Health Systems, USA.
Klein-Schwartz
Wendy
W
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000927:Anticonvulsants / Q000506:poisoning / Q000633:toxicity*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D004244:Dizziness / Q000139:chemically induced; D062787:Drug Overdose; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000506:poisoning / Q000633:toxicity; D006801:Humans; D008297:Male; D011039:Poison Control Centers / Q000706:statistics & numerical data; D011595:Psychomotor Agitation / Q000209:etiology; D012189:Retrospective Studies; D012894:Sleep Stages / Q000187:drug effects; D000077236:Topiramate; D014481:United States
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose